Glucagon-like peptides I and 2 in health and disease: A review

被引：69

作者：

Marathe, Chinmay S. ^{[1
,2
]}

Rayner, Christopher K. ^{[1
,2
]}

Jones, Karen L. ^{[1
,2
]}

Horowitz, Michael ^{[1
,2
]}

机构：

[1] Univ Adelaide, Royal Adelaide Hosp, Discipline Med, Adelaide, SA, Australia

[2] Univ Adelaide, Ctr Res Excellence Translating Nutr Sci Good Hlth, Adelaide, SA, Australia

来源：

PEPTIDES | 2013年 / 44卷

关键词：

Glucagon-like peptides; Postprandial glycemia; Incretin secretion; Gastric emptying; GASTRIC-INHIBITORY POLYPEPTIDE; BETA-CELL FUNCTION; TYPE-2; DIABETES-MELLITUS; PROGLUCAGON GENE-EXPRESSION; INCRETIN-BASED THERAPIES; BIPHASIC INSULIN ASPART; TWICE-DAILY EXENATIDE; GLYCEMIC CONTROL; FOOD-INTAKE; POSTPRANDIAL GLYCEMIA;

D O I：

10.1016/j.peptides.2013.01.014

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：75 / 86

页数：12

共 161 条

[31] The structure and function of the glucagon-like peptide-1 receptor and its ligands [J].

Donnelly, Dan .

BRITISH JOURNAL OF PHARMACOLOGY, 2012, 166 (01) :27-41

[32] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].

Drucker, Daniel J. ;

Buse, John B. ;

Taylor, Kristin ;

Kendall, David M. ;

Trautmann, Michael ;

Zhuang, Dangliang ;

Porter, Lisa .

LANCET, 2008, 372 (9645) :1240-1250

[33] The Safety of Incretin-Based Therapies-Review of the Scientific Evidence [J].

Drucker, Daniel J. ;

Sherman, Steven I. ;

Bergenstal, Richard M. ;

Buse, John B. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (07) :2027-2031

[34] PROGLUCAGON GENE-EXPRESSION IS REGULATED BY A CYCLIC AMP-DEPENDENT PATHWAY IN RAT INTESTINE [J].

DRUCKER, DJ ;

BRUBAKER, PL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (11) :3953-3957

[35]

DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475

[36] Induction of intestinal epithelial proliferation by glucagon-like peptide 2 [J].

Drucker, DJ ;

Ehrlich, P ;

Asa, SL ;

Brubaker, PL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7911-7916

[37] STIMULATION OF INSULIN-SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN [J].

DUPRE, J ;

ROSS, SA ;

WATSON, D ;

BROWN, JC .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1973, 37 (05) :826-828

[38]

EBERT R, 1983, DIABETOLOGIA, V24, P449

[39] Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39 [J].

Edwards, CMB ;

Todd, JF ;

Mahmoudi, M ;

Wang, ZL ;

Wang, RM ;

Ghatei, MA ;

Bloom, SR .

DIABETES, 1999, 48 (01) :86-93

[40] GLUCAGON GENE REGULATORY REGION DIRECTS ONCOPROTEIN EXPRESSION TO NEURONS AND PANCREATIC ALPHA-CELLS [J].

EFRAT, S ;

TEITELMAN, G ;

ANWAR, M ;

RUGGIERO, D ;

HANAHAN, D .

NEURON, 1988, 1 (07) :605-613

← 1 2 3 4 5 6 7 8 9 10 →